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It has now ascertained that the clinical manifestations of liver disease in the elderly population reflect both the cumulative
effects of longevity on the liver and the generalized senescence of the organism ability to adjust to metabolic, infectious,
and immunologic insults. Although liver tests are not significantly affected by age, the presentation of liver diseases such
as viral hepatitis may be subtler in the elderly population than that of younger patients.
Human immunosenescence is a situation in which the immune system, particularly T lymphocyte function, deteriorates
with age, while innate immunity is negligibly affected and in some cases almost up-regulated.
We here briefly review the relationships between the liver aging process and mast cells, the key effectors in a more
complex range of innate immune responses than originally though.
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Nearly 13% of the inhabitants of the United States are
aged more than 65 years; this percentage will increase
substantially over the next 50 years [1].
Although it can refer to any time-related process, the
term “aging” is commonly used for post-maturational pro-
cesses that lead to diminished homeostasis and increased
vulnerability. The altered homeostasis in older organisms
is probably the result of a genetic program that determines
responses to exogenous influences and increases the pre-
disposition to illness and death.
There are five main characteristics associated with aging
in mammals: 1) increased mortality after maturation;
2) changes in the biochemical and physical properties of
tissues; 3) a progressive decrease in physiological capaci-
ties; 4) a reduced ability to respond adaptively to environ-
mental stimuli; and 5) increased susceptibility and
vulnerability to disease [2-4].
It is now recognized that human aging is a complex
phenotype resulting from the continuous, lifelong adapta-
tion of the body to unrepaired molecular and cellular* Correspondence: maurizio.chiriva@ttuhsc.edu
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reproduction in any medium, provided the ordamage to the organism caused by a variety of external
and internal agents [5].
Several studies have highlighted that immunosenescence
occurs as the result of a chronic hyperstimulation of both
adaptive and innate immune system components [5-8],
which together with the accumulation of molecular scars
due to the progressive deterioration of molecular compo-
nents and pathways [9] leads to a peculiar immune status
characterized by a global loss of efficiency (Figure 1).
Although the human liver is not unscathed by the
process of aging, the changes it undergoes are minor com-
pared with other organ systems [10]. It has been
ascertained that there are no liver diseases specific to ad-
vanced age. However, the clinical course and management
of liver diseases in the elderly may differ in several aspects
from those of younger adults [11]. We here briefly discuss
the relationships between the liver aging process and mast
cells (MCs), the key effectors in a complex range of im-
mune responses.Aging and the immune system
Aging is associated with many physiological changes in a
variety of organs [12]. It is today recognized that many dis-
eases observed in the elderly have an immunological basis
and are associated with the decline of immune response
[13]. Clinically, the consequences of impaired immune
function in the elderly include an increased susceptibility
to infections, malignancies and autoimmunity [14-16]. Ittd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Immunosenescence. This phenomenon has been described as the result of a chronic hyperstimulation of the immune system
components. Innate immunity is generally thought to be relatively well preserved or enhanced during aging compared with adaptive immunity,
which is characterized by several alterations.
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of unprimed virgin T-lymphocytes by primed memory
T-lymphocytes subpopulations and to the accumulation of
cells with signal transduction defects [17]. T-lymphocytes
are more severely affected than B-lymphocytes. This is
mainly due to the involution of the thymus, which is al-
most complete at the age of 60 [18]. In humans, the thy-
mus is a central lymphoid organ devoted to thymocyte
differentiation and maturation, and is therefore the primary
source of circulating T-lymphocytes. Although its size con-
tinues to increase until it reaches its maximum absolute
weight during puberty, its functional compartments and T-
lymphocytes output activity diminish after the first years of
life onwards. Although it continues to serve as the site of
T-lymphocytes differentiation and maturation throughout
adulthood, the thymus undergoes a process known as invo-
lution, which is defined as a decrease in size, weight and
activity of the gland with advancing age [19,20].
Other immunological cells, including macrophages,
neutrophils, natural killer (NK) cells, and NKT lympho-
cytes, are affected by aging [21]. In addition, it has been
shown that aged dendritic cells (DCs) are less able to
stimulate T and B-lymphocytes, although the results of
studies in humans and rodents focusing on DCs and aging
are still conflicting.
Functional defects and altered frequencies of innate
and adaptive immune cells impair local responses at the
site of vaccine injection, hamper the generation of pri-
mary responses to neo-antigens, prevent the effective in-
duction of memory lymphocytes, and decrease the effect
of booster vaccination. As a result, antibody responses
of elderly vaccines are weaker and decline faster, and
long-term protective effects of vaccination cannot betaken for granted in elderly peoples [13,22-24]. Evidences
exists that immunization procedures are less effective at
older age than in young adults. Influenza virus vaccines
have generally proved limited in preventing morbidity and
mortality among the elderly because of the lower immuno-
logical protection that they may confer on older adults
compared to younger persons [25]. Additionally, the meas-
ure of anti-hepatitis virus and anti-Hepatitis B surface anti-
bodies (anti-HBs) in elderly people after a combined
hepatitis virus A and B vaccination has underlined the de-
creased response to vaccination with increasing age [25].
It is now accepted that aging is characterized by a
peculiar state of chronic inflammation (the so-called
“inflamm-aging”) under genetic control, which seems to
be a consequence of a person’s life-long antigenic load
[26-30] and leads to a long-term tissue-related risk of all-
cause mortality in older people [31,32]. A number of stud-
ies have highlighted that chronic inflammation is the
underlying biological mechanism responsible for the
decline in physical function observed in the elderly [33].
It has also been shown that aging is accompanied by a
2-4-fold increase in the plasma levels of inflammatory me-
diators, cytokines and acute-phase proteins [34-37]. Add-
itionally, human aging is associated with a deregulated
cytokine response following stimulation: chemotaxis and
phagocytosis, as well as antigen processing and presenta-
tion, are all depressed in the elderly, whereas cell activa-
tion and the secretion of pro-inflammatory cytokines such
as interleukin (IL)-1β, IL-6 and Tumor-Necrosis Factor
(TNF)-α are markedly increased. Recently, it has been
reported that inflammation in excess is detrimental, and
that excessive production and secretion of cytokines may
lead to pathology [25]. Kundu and Surh evidenced that a
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that inflammatory markers are significant predictors of
mortality in old humans [38]. It is widely accepted that
many aging-related diseases, including cardiovascular dis-
eases, atherosclerosis, Alzheimer’s disease and diabetes,
share a common inflammatory background.
Aging and the liver
The incidence of liver disease increases with age while the
ability to withstand a hepatic insult falls with each decade
[39]. It is indubitable that interest in the role of aging in
the sphere of hepatology has increased, especially with the
recent recognition of the critical importance of age in de-
termining the clinical outcome in chronic hepatitis C virus
(HCV) infection and the influence of donor age on graft
survival after liver transplantation [39]. Human and ex-
perimental studies suggest that, in comparison with other
organs, the liver ages fairly well [40]. Aging is however as-
sociated with a variety of morphological changes in the
liver [40,41], but their underlying mechanisms are still un-
clear. The liver progressively shrinks by 20-40% during the
course of a human life [42-44], and there is a concomitant
age-related decrease in liver volume [43,45]. The classic
gross appearance of the liver in the elderly is known as
“brown atrophy”, and the brown is due to an accumulation
of highly oxidized insoluble proteins, known as lipofuscin,
stored into hepatocytes. These accumulations of highly
cross-linked protein are thought to relate to chronic oxi-
dative stress and a failure to degrade damaged and dena-
tured proteins [39]. Increasing evidence suggests that
lipofuscin interferes with complex cellular pathways due
to its ability to trap metallic cations and facilitate further
free radical formation. Other sub-cellular hepatocyte
changes with age involves a marked decline in smooth
endoplasmic reticulum surface, which correlates with de-
creased hepatic microsomal protein concentrations and
enzymatic activity including glucose-6-phosphatase; fur-
thermore, the human liver tends to develop macro and
polyploid hepatocytes with increased nuclei and nucleoli
during aging [46]. Kudryavtsev et al. reported that after
the age of 85, around 27% of human hepatocytes demon-
strate polyploidy compared to around 6% for individuals
in their twenties [47].
One of the most important age-related changes in liver
function observed in animal models is a significant de-
crease in regenerative capacity of the liver, but not in the
capacity to restore the organ to its original volume [48].
Liver regeneration in both young and old animals was
complete by day 7 after 70% hepatectomy, but at day 1
younger animal had significantly increased liver mass and
increased intrahepatic mitotic activity. It has also been
shown that aging is associated with multiple changes in
[49-53]. Elderly humans secrete less bile acid, have in-
creased biliary cholesterol levels, and show an increasedoxidative stress that is mainly attributable to a reduced
capacity to eliminate metabolically generated superoxide
radicals as efficiently as before [41]. The reduction in hep-
atic blood flow during aging reduces the metabolism of
rapidly cleared drugs [54]. Aging of the liver is also associ-
ated with impaired metabolism of drugs, adverse drug in-
teractions, and susceptibility to toxins [53,55]. Additionally,
it is now accepted that drug [53] and pharmacodynamics
may be altered in the elderly. An important contribution is
made by decreased renal function, but biotransformation
in the liver may also play a fundamental role [56,57].
Serum bilirubin and classical enzymes unchanged with
aging [58]. However, sensitive tests of liver function have
revealed a small decline with aging. This has been con-
firmed in experimental studies that have demonstrated
changes in mRNA in the genes involved in cell stress and
fibrosis [59]. Albumin synthesis decreased slightly with age,
but this seems to be secondary to increased cytokine pro-
duction owing to the levels of chronic inflammation [60].
Older people have a higher incidence of acute liver
failure and a higher mortality with acute hepatitis A
[61,62]. Along with the considerable growth in Western
societies of relatively healthy elderly populations, it is in-
evitable that there will also be an increase in the number
of elderly people with chronic liver diseases (mainly
hepatitis C virus (HCV)-related cirrhosis, alcoholic cir-
rhosis and HCC).
Poynard et al. showed that age at HCV infection was a
main risk factor for fibrosis [63,64]. The rate at which fi-
brosis progressed was low in individuals infected when
younger than 20 years, intermediate in those infected at
age 21 to 40 years, increased in those infected at age 40 to
50 years, and highest in those infected at 50 years of age
or older. The reason for more rapid progression of liver fi-
brosis in older patients affected by HCV is still unknown,
but seems to be related to the decline in immune function
with age. Hartmann et al. showed that telomere shorten-
ing (the telomere length of somatic cells becomes shorter
with aging because of the “end replication problem”) rep-
resents a causal factor impairing liver regeneration and ac-
celerating cirrhosis formation in response to chronic liver
disease [65].
Age is an independent risk factor for poor outcome in
primary biliary cirrhosis (PBC) in addition to the presence
of portal hypertension and impaired liver function [66-68].
It has been hypothesized that the increased susceptibility
of aging people to neoplastic diseases are due to a de-
crease in basic immune defense functions [39,69].
It is well recognized that the incidence of HCC in pa-
tients with HCV correlates with progression of liver fi-
brosis. However, there is little information on the impact
of aging on hepatocarcinogenesis. Furthermore, it is not
known whether the putative etiologic factors and clinical
and pathological features of HCC differ between young
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oped HCC more often, despite their lower grade of fibro-
sis, compared with the younger patients. Youssef et al.
reported that the hepatocarcinogenic effect of Peroxisome
Proliferator-Activated Receptor Alpha (PPAR alpha)
agonists is enhanced by aging [71]. Exposure to these
chemicals produces a five- to seven-fold higher yield of
grossly visible hepatic tumors in old relative to young
animals [71]. Newer evidence indicates an active age-
related change in the regulation of malignant hepatocyte
proliferation. Substantial attention has focused on the
telomere/telomerase system as a mediator of replicative
capacity. Telomeres are repeating hexanucleotide se-
quences that function to protect chromosomes against
chromosomal end-end fusion and non-reciprocal translo-
cations. Telomerase is a reverse transcriptase consisting of
enzymatic (TERT), RNA template (TERC) and several
other protein components including heat-shock protein
90 (hsp90) and dyskerin [39,72]. Telomerase can maintain
telomere length by adding TTAGGG repeats, but its ex-
pression is controlled in differentiated and stem-cell popu-
lations [73-75]. Short human telomeres have been linked
to the subsequent onset of disease and death in healthy
older persons [76]. Kitada et al. [77] and Urabe et al. [78]
showed that subjects with chronic viral hepatitis had
shorter hepatic telomeres than healthy controls and that
increasing fibrosis was associated with shorter telomere
lengths. The role of the telomere/telomerase system in the
pathogenesis of HCC have led some to suggest that thera-
peutic manipulation may hold the promise for future ther-
apies [39]. Telomerase inhibitors are currently in phase II
clinical trials and would represent a rational therapy for
HCC. However, the potential for inducing fatal liver fail-
ure, given the results from mouse models, may limit their
safety and efficacy.
Mast cells: a heterogeneous innate immune cell
population
Mast cells (MCs) have a rather unique position among cells
of the immune response. Paul Ehrlich first described MCs
in his 1878 doctoral thesis: he called them “mastzellen”
(maestung - a root of the English word mastication; the
active form “measten” is still in use) because of their char-
acteristic staining of proteoglycan and protease-rich cyto-
plasmic granules. Ehrlich also noted the tendency of MCs
to be associated with blood vessels, nerves, and glandular
ducts.
It has been estimated that human MCs contain 2.4 to
7.8 μg heparin per 106 cells [79]. This observation, along
with the knowledge that heparin is a negatively charged
molecule helps explain why MC granules are preferen-
tially stained with cationic dyes [80]. In their traditional
role, MCs are key players in immunoglobulin E (IgE)-as-
sociated immune responses via aggregation of the high-affinity IgE receptor, FcεRI, that is expressed on MCs as a
heterotetrameric receptor with subunits that initiate spe-
cific signaling events [81]. Both positive and negative effects
are elicited by FcεRI, which includes degranulation, gene
transcription and eicasanoid production. More recently, it
has been noted that MCs are not regulated solely by IgE-
dependent mechanisms. New reports show that MCs ex-
press other surface receptor binding sites such as Toll-like
receptors (TLRs), β2-integrins, intercellular adhesion
molecule-1 (ICAM-1), androgen receptors, purinergic P2X
receptors (P2X1, P2X4 and P2X7) and the serotonin recep-
tor, 5-HT1A [81].
It has long been recognized that MCs elicit allergic
symptoms [82], but it is now widely accepted that they
are multifunctional effector cells of the immune system,
although the various phases of their differentiation are
still only partially known. It was initially suggested that
they derive from T lymphocytes, fibroblasts or macro-
phages, but the current general consensus suggests that
they originate from pluripotent hemopoietic stem cells
in bone marrow, from where they are released into the
blood as progenitors before they undergo terminal dif-
ferentiation by invading connective or mucosal tissue as
morphologically unidentifiable MC precursors and then
differentiating into phenotypically identifiable MCs [83]
(Figure 2). It has been demonstrated that MC are long-
lived cells [83].
MCs are found in almost all of the major organs of the
human body, and in several body sites that come into
contact with the external environment, including the
skin, respiratory system and digestive tract. These main
accumulations in sites where foreign material attempts
host invasion suggest that MCs are one of the first cell
populations to initiate defense mechanisms.
The ability of the lineage to generate individual MC
populations with different biochemical and functional
properties gives them greater diversity and flexibility in
meeting the requirements of the physiological, immuno-
logical, inflammatory or other biological responses in
which they may be involved [84-88].
A number of Authors have identified a local or systemic
increase in the number of MCs in various pathological
conditions, including interstitial pneumonia, ulcerative
colitis, intestinal helminthosis and ectodermal parasitosis,
as well as skin disorders such as atopic dermatitis, psoria-
sis, scleroderma and wound healing, and various neoplas-
tic diseases [89-92].
Tryptases and chymases are the major proteases compo-
nents of MC secretory granules. There are two well-known
human MC classes that are distinguished by enzymatic im-
munostaining for mast cell proteases, tryptase (MCT) alone
or tryptase and chymase together (MCTC). MCT are found
mainly in mucosal sites whereas MCTC [93]. These two
populations of MCs exhibit functional differences [84].
Figure 2 Mast cells origin and differentiation. It was initially suggested that Mast cells derive from T lymphocytes, fibroblasts or macrophages,
but the current general consensus suggests that these immune cells originate from pluripotent hemopoietic stem cells in bone marrow, from
where they are released into the blood as progenitors before they undergo terminal differentiation by invading connective or mucosal tissue as
morphologically unidentifiable Mast cells precursors and then differentiating into phenotypically identifiable Mast cells.
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MCs in 1990 [87,92]. Other MC products include interleu-
kins (IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-11, IL-12, IL-13,
IL-15, IL-16, IL-18, IL-2), chemokines (macrophage
inflammatory protein alpha [MIP-1]), hematopoietic
factors (granulocyte macrophage colony stimulating
factor [GM-CSF]), stem cell factor (SCF), growth fac-
tors (transforming growth factor beta [TGF-β], vascu-
lar endothelial growth factor [VEGF], nerve growth
factor [NGF]), several metalloproteinases, heparin,
histamine, chondroitin sulfates, cathepsin, carboxy-
peptidases and peroxidase [84,87].
These products may be released when MCs are activated
via IgE- or IgG-dependent mechanisms, and may also be
produced under other circumstances such as in response to
stimulation by bacterial products through Toll-like recep-
tors (TLRs) [94].
MCs and IgE have long been associated with the patho-
genesis of the acute manifestations of the immediate
hypersensitivity reaction, the pathophysiologic hallmark of
allergic rhinitis, allergic asthma, and anaphylaxis. The cen-
tral role of MCs in these disorders is now widely accepted.
Additionally, MCs are considered to be critical effectors in
many human inflammatory diseases, and the core of an
immediate hypersensitive reaction: they have been incrim-
inated in different diseases including allergy, asthma,
rheumatoid arthritis, arteriosclerosis, chronic graft-versus
-host disease, fibrotic disease, ischemic heart disease and
malignancy, and contribute to the progression of chronic
diseases [95-99]. Any alteration in cell programs that de-
termines a requirement for MC degranulation may there-
fore have a considerable impact on disease severity.Nguyen et al. have shown the ability of Prostaglandin E2
(PGE2) to initiate MCs degranulation changes in the aging
animal, thus suggesting that aging induces reprogramming
of MC degranulation [100].
The parenchyma of the liver is a complicated structure
with numerous cell types having different functions in
normal liver function and disease response. These include:
Kupffer cells, hepatic stellate cells, sinusoidal endothelial
cells, vascular endothelial cells, fibroblasts and pit cells.
The majorities of these cells play definitive roles in liver
pathophysiology and interact with hepatic MCs (Figure 3).
MC quantity has been shown to increase in PBC by stain-
ing for either toluidine blue or immunohistochemical
staining for tryptase and chymase, evidence that these cells
are presumably MCTC. Increased plasma histamine levels
were also found in patients with PBC, in contrast to
healthy patients, raising the possibility of a role for in vivo
mast cell activation and mediator release in these diseases
[101]. Hepatic MC expression and quantity have been also
shown to increase in patients with primary sclerosing
cholangitis (PSC) compared to healthy controls. Increased
MC infiltration has been noted in bile ducts in patients
with early stage PSC with a diffuse staining in the fibrous
septa in the late stage of PSC [102].
Mast cells and liver aging
It has been recognized that liver MCs are present under
normal and pathological conditions in both humans
and experimental animals [87]: normal human livers
have only ≈1.2-3.9 MCs/mm2, but rat livers have 1.8-12
MCs/mm2 [87]. Immunostaining with antibodies against
chymase or tryptase, or metachromatic dyes, has shown
Figure 3 Mast cells and the liver cell interactions. The parenchyma of the liver is a complex structure with different cell types having various
functions in normal liver function and disease response. These include: macrophages, or Kupffer cells, hepatic stellate cells, sinusoidal endothelial
cells, vascular endothelial cells, fibroblasts and pit cells. It has been ascertained that all these cells (in addition to biliary cells) play definitive roles
in liver pathophysiology and determine complex interactions with hepatic MCs.
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ive tissues adjacent to hepatic arteries, veins and bile ducts
of the portal tracts [87].
MCs seem to be involved in the liver’s fibrotic response
to chronic inflammation [103] and parasitic infection as
different studies have established that they can induce liver
fibrosis in humans and animal models following liver
damage caused by autoimmune reactions, chemical toxins,
viral infections and cholestasis [87]. However, it has also
shown that MCs play no primary role in liver fibrosis in
mast cell-deficient rodents [87] and, as there is no signifi-
cant relationship between chymase activity in liver tissue
and the severity of liver fibrosis, the role of MCs in liver
fibrogenesis remains a subject of controversy [87].
MCs infiltrating portal tracts and surrounding dam-
aged bile ducts have also been found in patients with
chronic allograft rejection, thus suggesting that they may
be important effector cells in the pathogenesis of chronic
transplanted liver rejection [87]. The liver is also affected
during systemic mastocytosis, a clonal disorder of MCs
and their progenitors that is characterized by abnormal
MC proliferation in different organs [80,87]. Finally, it
has been associated MCs and angiogenesis in liver neo-
plasia because the significant correlation between MCs
and microvessel density suggests they may play a role in
tumor progression by promoting angiogenesis [90].
MCs have recently been investigated in order to study
their involvement in the mechanisms leading to age-
related chronic diseases. During fibrosis and hepatic dis-
ease progression (i.e. hepatitis), hepatocytes maintain a
close interaction with other resident cell types as well as
inflammatory cells. These populations come together toinduce “sinusoidal capillarisation” which describes the
events that cause the sinusoids to resemble capillaries.
Capillarisation inhibits the normal processes of exchange
between hepatocytes and plasma and has been found to
be a condition that worsens liver function. It has been
showed that liver sinusoidal endothelial cells become
thicker and defenestrated, there is a sporadic deposition of
collagen and basal lamina in the extra-cellular space of
Disse, and the number of non-activated stellate or Ito cells
increases [41]. This pseudo-capillarization leads to relative
hypoxia of hepatocytes in older rats and may be reflected
by lower ATP/ADP ratios in older versus younger rats
[41,54,55,57]. In humans, these morphological changes
have potential clinical implications, including adverse drug
reactions and acute hepatitis [104-109].
In old age, there is a 30-50% reduction in the area of the
endothelium perforated by fenestrations (“porosity”). This
is associated with increased endothelial thickness and extra-
cellular matrix in the space of Disse, including collagen and
basal lamina [41,110-112]. These ultrastructural changes
are associated with increased expression of antigens not
usually expressed in young healthy livers such as von
Willebrands factor and collagen IV. DeLeve et al. [113]
demonstrated that sinusoidal endothelial cells prevent hep-
atic endothelial cells activation and also promote reversion
of activated hepatic endothelial cells to a quiescent pheno-
type, whereas capillarized sinusoidal endothelial cells lose
this effect. Coupled with the in vivo observation in humans
and in animal models that capillarization precedes fibrosis,
the findings in this study suggest that capillarization of si-
nusoidal endothelial cells may be permissive for hepatic
endothelial cell activation and fibrosis. A role for mast cells
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mast cells contribute to capillarisation by recruiting other
liver matrix-producing cells, thus increasing the secretion
of cytokines and other mediators during the progression
of liver fibrosis [87]. A variant of capillarization called
pseudocapillarization is seen with aging [110-112].
It has been shown that MC density increases with age
[114-120] but, although human and experimental studies
have revealed many of the roles played by MCs in physio-
logical and pathological conditions, there is still debate
concerning their function as the critical initiators of in-
flammatory reactions, and whether they can be considered
an early index of acute liver injury.
Recently it has been evaluated MC density in liver tissues
taken from untreated and CCl4-treated young (2 months),
middle-aged (6 and 12 months) and old male rats (19
months) as a quantitative index of acute toxic liver inflam-
mation, and investigated whether the density is age-
dependent [121,122].
Histological examinations of the 12- and 19-month
-old rats sacrificed two hours after CCl4 intoxication
showed hepatocyte necrosis and inflammatory cell infil-
tration in the perivenular areas, whereas the periportal
areas were virtually unaffected.
It was found no statistical differences in MC density be-
tween the untreated rats of different ages, but MC density
was considerably increased in the young rats both two and
24 hours after CCl4 intoxication, with the 24-hour differ-
ence being statistically significant. The increase in MC
density was less marked in the 19-month-old rats than in
the young rats, but there were significant differences be-
tween the untreated rats and the treated rats two hours
after CCl4 intoxication, and between the densities mea-
sured two and 24 hours after intoxication. The changes in
the rats aged six and 12 months fell between those ob-
served in the rats aged two and 19 months.
It is well known that MCs are a primary cell population
involved in inflammatory responses. By means of the rapid
release of their pro-inflammatory molecules, MCs deter-
mine a series of events that lead to both immediate and
late-phase responses.
Quantitative analysis of MC density in untreated rats
and rats receiving an intraperitoneal injection of CCl4
highlighted the fact that MC density is an important
marker of an acute liver inflammatory reaction to toxic
CCl4 damage: it considerably increased two hours after
intoxication (which suggests that MC cells are recruited
early in injured tissue) and the increase was even more
evident after 24 hours, when the density was signifi-
cantly greater than in the control animals [121]. As MC
density two and 24 hours after intoxication was greater
in the young than in the oldest rats, this suggests that
the latter have fewer MC recruiting stimuli and that
young rats are characterized by a rapid response to toxicinjury. This different behavior is in line with theoretical
models showing that a large number of biological events
are age-dependent. Future studies of inflammatory reac-
tions could investigate the relationships between MC
biology, age and functional activities (metabolism) in hu-
man patients. In fact, although most theories of aging
assume that cell functions decline with aging, many
intracellular functions in the liver, such as enzyme activ-
ities, stay fairly stable in old age.
Conclusions
It is indubitable that aging, being a complex process,
involves an array of intertwined molecular pathways
[123,124]. Simultaneous study of multiple molecular
pathways in parallel could provide invaluable informa-
tion in understanding the clinical course of liver aging
and elucidating mechanisms that play key roles in the
aging process. Recent observations indicate that immuno-
senescence is the result of a remodeling where some func-
tions are reduced, others remain unchanged or even
increased. In addition, it appears that the non-adaptive
compartment of the immune system is relatively preserved
during aging in comparison to the more recent and sophis-
ticated adaptive compartment that exhibit more profound
modifications [125]. On the basis of the above observations,
the following conclusions are made: a) the incidence of liver
disease increases in the elderly, but the cellular and sub-
cellular perturbations underlying this predisposition to
pathology remain still unresolved. b) Although the liver
ages fairly well, several age-related morpho-functional
changes have been highlighted, including: a) a decline in
liver volume; b) an increase in the hepatic pigment
(lipofuscin) deposition; c) a moderate decline in the Phase I
metabolism of certain drugs; d) shifts in the expression of a
variety of proteins and e) diminished hepatobiliary func-
tions. Other more subtle changes may contribute to in-
creased susceptibility to certain liver diseases in the elderly
[126]. e) Aging of the liver mainly affects the sinusoids.
Pseudo-capillarization, manifested by reduced sinusoidal
fenestration and subendothelial collagen deposition, causes
a reduction in oxygen-dependent hepatocyte functions such
as oxidative drug metabolism [127]. f) Reduced hepatic
blood flow in the elderly has been suggested to be the
major effect of aging on the liver circulation. g) MCs can
exert positive or negative immunomodulatory effects on
immune cells by influencing the recruitment, survival, de-
velopment, phenotype or function of immune cells and
thereby enhance or suppress the initiation, magnitude and/
or duration of immune responses [128]. h) Quantitative
analysis of MC density in liver specimens taken from un-
treated rats and rats receiving an intraperitoneal injection
of CCl4 highlighted the fact that MC density is an import-
ant marker of acute liver inflammation. i) MC density two
and 24 hours after CCl4 intoxication was greater in the
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have fewer MC recruiting stimuli and that young rats are
characterized by a rapid response to toxic injury.
In conclusion, a better understanding of the mechanisms
underlying the age-related liver changes may help to pre-
serve hepatic function, improve morbidity and mortality,
and hopefully reduce healthcare costs for the aging popula-
tion. Additionally, it is likely that future studies of MCs in
experimental models and human tissues will reveal more
about their functions not only in the pathogenesis of liver
and other diseases, but also in the immunosenescence
process affecting human tissues.
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